Evidence map›Paper›PMID 41838128›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Neuroprotective effects of Interleukin-1 receptor antagonism after cardiac arrest: an experimental rat study.

Bilal Arslan, Fatma Ayaz Yalınkılıç, Adnan Erseçkin, Burhan Beger, Bilal Acar, Utku Batu, Mehmet Mehdi Oğuz, Abdulaziz Yalınkılıç, Orhan Beger, Mehmet Zeki Erdem and 1 more

Abstract read
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bilal ArslanDepartment of Pediatrics, Van Yüzüncü Yıl University Faculty of Medicine, Van, Turkey. arslanbilal_351@hotmail.com.ORCID 0009-0001-3907-0888
Fatma Ayaz YalınkılıçDepartment of Pathology, Van Yüzüncü Yıl University Faculty of Medicine, Van, Turkey.ORCID 0000-0002-7590-7999
Adnan ErseçkinDepartment of Pediatrics, Van Yüzüncü Yıl University Faculty of Medicine, Van, Turkey.ORCID 0000-0002-3105-2749
Burhan BegerDepartment of Pediatric Surgery, Van Yüzüncü Yıl University Faculty of Medicine, Van, Turkey.ORCID 0000-0002-1565-8062
Bilal AcarDepartment of Pediatrics, Ağrı Private Lena Hospital, Ağrı, Turkey.ORCID 0009-0009-5244-706X
Utku BatuDepartment of Pediatrics, Van Regional Training and Research Hospital, Van, Turkey.ORCID 0000-0002-4434-1670
Mehmet Mehdi OğuzDepartment of Pediatrics, Van Regional Training and Research Hospital, Van, Turkey.ORCID 0000-0003-2025-4983
Abdulaziz YalınkılıçDepartment of Otorhinolaryngology, Van Yüzüncü Yıl University Faculty of Medicine, Van, Turkey.ORCID 0000-0003-2702-5905
Orhan BegerDepartment of Anatomy, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.ORCID 0000-0002-4932-8758
Mehmet Zeki ErdemDepartment of Otorhinolaryngology, Van Yüzüncü Yıl University Faculty of Medicine, Van, Turkey.ORCID 0000-0003-3263-4633
Halit DemirDepartment of Biochemistry, Van Yüzüncü Yıl University Faculty of Medicine, Van, Turkey.ORCID 0000-0001-5598-2601

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the histopathological and biochemical neuroprotective effects of IL-1 receptor antagonist (anakinra) administration in an asphyxia-induced cardiac arrest model. A total of 24 Wistar albino rats were randomized into three groups: control, sham (cardiac arrest + saline), and anakinra (cardiac arrest + 50 mg/kg anakinra). Brain tissues were evaluated using a six-parameter semi-quantitative histopathological scoring system, and the composite damage score (CDS) was calculated (0-12). Levels of antioxidant and oxidative markers SOD, CAT, GSH, and MDA were analyzed spectrophotometrically. In the anakinra-treated group, neuronal degeneration, gliosis, and neuropil edema levels were significantly lower compared to the sham group (p < 0.01 for all). Although vascular congestion and perivascular edema were observed to be lower in the anakinra group, this reduction was not statistically significant in score analyses compared to the sham group (p > 0.05). No significant difference was found between the groups in terms of PMNL infiltration. In biochemical analyses, SOD, CAT, and GSH levels were found to be significantly higher in the anakinra group compared to both the sham and control groups (p < 0.001), while MDA levels were significantly lower (p < 0.001). These findings indicate that anakinra reduces oxidative stress and significantly alleviates neurohistopathological damage in the experimental model. Anakinra administration significantly reduced short-term hypoxic-ischemic brain damage following cardiac arrest, both in terms of histopathological and oxidative stress parameters. The findings suggest that targeting the IL-1-mediated inflammatory response could be an important neuroprotective approach; however, further studies are needed regarding dose, timing of administration, and long-term neurological function.

Indexed as

Heart ArrestInterleukin 1 Receptor Antagonist ProteinNeuroprotective AgentsReceptors, Interleukin-1AnimalsAntioxidantsBrainDisease Models, AnimalGlutathioneMaleOxidative StressRatsRats, WistarAntioxidantsGlutathioneInterleukin 1 Receptor Antagonist ProteinNeuroprotective AgentsReceptors, Interleukin-1AnakinraCardiac arrestExperimental modelIL-1 receptor antagonistNeuroinflammationNeuroprotectionOxidative stress

Identifiers

PMID41838128
PMCPMC13269372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.